4519.T实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 14:15):

Stats
今日成交量	4.61M
平均成交量	2.52M
市值	7 983.40B
EPS	¥45.22 ( 2024-04-24 )
下一个收益日期	( ¥52.88 ) 2024-07-25
Last Dividend	¥40.00 ( 2023-06-29 )
Next Dividend	¥0 ( N/A )
P/E	24.45
ATR14	¥4.69 (0.10%)

音量相关性

長: -0.43 (neutral)

短: -0.81 (strong negative)

Signal:(28.37) Be Aware. Possible trading coming up! (swing)

Chugai Pharmaceutical 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Chugai Pharmaceutical 相关性 - 货币/商品

-0.07
( neutral )

-0.08
( neutral )

0.03
( neutral )

-0.17
( neutral )

-0.10
( neutral )

0.38
( neutral )

Chugai Pharmaceutical 财务报表

Annual	2023
营收:	¥1 111.37B
毛利润:	¥693.01B (62.36 %)
EPS:	¥197.83

FY	2023
营收:	¥1 111.37B
毛利润:	¥693.01B (62.36 %)
EPS:	¥197.83

FY	2022
营收:	¥1 259.95B
毛利润:	¥783.70B (62.20 %)
EPS:	¥227.64

FY	2021
营收:	¥999.76B
毛利润:	¥661.61B (66.18 %)
EPS:	¥184.37

Financial Reports:

No articles found.

Chugai Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥40.00 (N/A)	¥0 (N/A)	¥40.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Chugai Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.15 - good (81.48%) | Divividend Growth Potential Score: 5.92 - Stable (18.36%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥0.500	2000-03-28
Last Dividend	¥40.00	2023-06-29
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	48	--
Total Paid Out	¥538.17	--
Avg. Dividend % Per Year	0.00%	--
Score	3.59	--
Div. Sustainability Score	8.15
Div.Growth Potential Score	5.92
Div. Directional Score	7.03	--

Next Divdend (Est)
(2024-10-10)

¥0 Estimate 3.74 %

Dividend Stability

0.30 Very Poor

Dividend Score

3.59

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8285.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7673.T	Ex Dividend Junior	2024-05-30	Annually	0.00%
6855.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6203.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
4929.T	Ex Dividend Junior	2024-03-18	Annually	0.00%
4099.T	Ex Dividend Junior	2023-12-28	Semi-Annually	0.00%
3315.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
2384.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
9312.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
8043.T	Ex Dividend Junior	2024-03-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.315	1.500	3.70	5.55	[0 - 0.5]
returnOnAssetsTTM	0.172	1.200	4.27	5.12	[0 - 0.3]
returnOnEquityTTM	0.207	1.500	8.81	10.00	[0.1 - 1]
payoutRatioTTM	0.402	-1.000	5.98	-5.98	[0 - 1]
currentRatioTTM	5.53	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.21	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.937	1.500	0.351	0.526	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	18 133	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	233.57	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	197.34	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.677	1.000	2.05	2.05	[0.2 - 0.8]
operatingProfitMarginTTM	0.420	1.000	3.60	3.60	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.546	0.800	9.69	7.75	[0.5 - 2]
Total Score				8.15

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.46	1.000	7.63	0	[1 - 100]
returnOnEquityTTM	0.207	2.50	9.24	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	197.34	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	1.649	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	233.57	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.402	1.500	5.98	-5.98	[0 - 1]
pegRatioTTM	0.435	1.500	-0.430	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.371	1.000	3.23	0	[0.1 - 0.5]
Total Score				5.92

Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.